Cenix Adds Respiratory, Inflammatory Diseases to RNAi-Screening Deal With AstraZeneca | GenomeWeb

Cenix BioScience announced this week that it has signed multi-year deal to use its RNAi screening technology to discover novel drug targets for respiratory and inflammatory disease for AstraZeneca.

According to Cenix, the deal expands upon the companies' existing research arrangement in oncology, which was signed in 2008 (see GenomeWeb Daily News, 3/19/2008).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.